Steven Chrzanowski, MD
Internal Medicine · Great Falls, MTNPI 1568454692
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $817 and has fallen 82.3% since, to $144 in 2025. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$413
- GSK$332
- Amgen$270
- Merck$209
- E.r. Squibb & Sons, L.L.C.$152
- Pfizer$107
- plus $530 from 18 others
What the payments were for
- Food & beverage$2,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $413 |
| GSK | 22 | $332 |
| Amgen | 15 | $270 |
| Merck | 16 | $209 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| Pfizer | 8 | $107 |
| Novartis | 5 | $75 |
| Novo Nordisk | 5 | $71 |
| AbbVie(2 entities) | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Johnson & Johnson(2 entities) | 3 | $40 |
| Astellas Pharma US Inc | 2 | $32 |
| Lilly USA, LLC | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Verona Pharma, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Lundbeck LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,012 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 305 | $284,618 |
| TrulicityDulaglutide | 90 | $118,996 |
| OzempicSemaglutide | 72 | $108,709 |
| FarxigaDapagliflozin Propanediol | 70 | $84,503 |
| JardianceEmpagliflozin | 76 | $81,730 |
| XareltoRivaroxaban | 70 | $71,137 |
| JanuviaSitagliptin Phosphate | 59 | $58,291 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $29,712 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $28,160 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $26,503 |
| Bydureon BciseExenatide Microspheres | 19 | $26,223 |
| MyrbetriqMirabegron | 26 | $21,482 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $20,704 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $18,000 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $15,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro | $107 | $287,869318 claims |
| Lilly USA, LLCTrulicity | $28 | $118,99690 claims |
| Novo NordiskOzempic | $71 | $108,70972 claims |
| AstraZenecaFarxiga, Symbicort | $413 | $92,16486 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $18 | $91,34897 claims |
| Johnson & JohnsonXarelto, Invokana | $40 | $78,56482 claims |
| MerckJanuvia | $209 | $58,29159 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $332 | $37,85538 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $21,48226 claims |
| AbbVieLinzess | $63 | $13,98615 claims |
| Sanofi-aventis U.S. LLCLantus | $24 | $3,16121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Great Falls
- Stacy KingslandGreat Falls$5K
- Nicholas TrumGreat Falls$2K
- Bradford BergmanGreat Falls$2K
- Scott BurkGreat Falls$1K
- Kathleen BlairGreat Falls$1K
- Katherine ZitelloGreat Falls$682
- Eve GerasimouGreat Falls$661
- Berilonson OsiroGreat Falls$340
- James LeganGreat Falls$312
- Hanna BroniewskaGreat Falls$193
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.